Innovators in Hemoglobinopathies Academic Career Development Award (K07)

The summary for the Innovators in Hemoglobinopathies Academic Career Development Award (K07) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Innovators in Hemoglobinopathies Academic Career Development Award (K07): Purpose. The purpose of the NHLBI Innovators in Hemoglobinopathies Academic Career Development Award is to provide support for salary and research costs for up to 4 years for individuals with medical or doctoral degrees in clinical fields who are not fully established investigators and who want to pursue research careers in sickle cell disease and/or the thalassemias. The primary objective of this program is to advance the research career development of clinician scientists who have implemented innovative programs for patients with sickle cell disease and/or the thalassemias but have not been on a research track. These awards will provide support to clinician scientists who would not be eligible for other NHLBI mentored K awards, i.e., K23, K01, K08, or K25 (http://www.nhlbi.nih.gov/funding/training/redbook/newintro.htm). Prospective Candidates are encouraged to contact the NHLBI staff for specific programmatic and budgetary information (see Section VII. Agency Contacts of this FOA). Mechanism of Support. This FOA will utilize the K07 award mechanism. Candidates must commit a minimum of nine person months (75%) effort to activities covered under the award. Funds Available and Anticipated Number of Awards. The NHLBI intends to commit $2.484 million total costs in FY2011 to support meritorious projects solicited through this RFA. The NHLBI expects to award 6 grants for a total of $9,936,000 in funds over the 4-year project period.

Federal Grant Title:	Innovators in Hemoglobinopathies Academic Career Development Award (K07)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-10-021
Type of Funding:	Grant
CFDA Numbers:	93.839
CFDA Descriptions:	Blood Diseases and Resources Research
Current Application Deadline:	Sep 14, 2010
Original Application Deadline:	Sep 14, 2010
Posted Date:	Jun 29, 2010
Creation Date:	Jun 29, 2010
Archive Date:	Oct 15, 2010
Total Program Funding:	$2,484,000
Maximum Federal Grant Award:	$414,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) .
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immu...; • New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional); • Limited Competition: Sickle Pan-African Research Consortium Clinical Coordinating Center (...; • Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional); • Limited Competition: Sickle Africa Data Coordinating Center (U24 Clinical Trial Optional); • Improved Therapy for Hemophilia and Hereditary Bleeding Disorders; • Clinical Hematology Research Career Development Program (K12); • Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow F...
More Grants from the National Institutes of Health: • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)